XML 32 R14.htm IDEA: XBRL DOCUMENT
v3.22.1

Note 8 - Subsequent Events | 12 Months Ended
--- | ---
Dec. 31, 2021
Notes to Financial Statements |
Subsequent Events [Text Block] | Note 8: Subsequent Events For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March 29, 2022, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements. Stock Option Grant On January 3, 2022, the Company granted to executives and key personnel an aggregate of 325,000 stock options with an exercise price of $4.81. The options will vest in one year from the date of grant or annually in equal installments over four years. On January 3, 2022, the Company granted 75,000 performance-based stock options to a key personnel with an exercise price of $4.81. The options will vest upon the achievement of specified performance conditions. On January 3, 2022, the Company granted to members of the Board an aggregate of 277,500 stock options with an exercise price of $4.81. The options will vest in one year from the date of grant. On January 3, 2022, the Company granted to non-executive employees an aggregate of 23,325 stock options with an exercise price of $4.81. The options will vest annually in equal installments over four years. On January 3, 2022, the Company granted 15,000 stock options to a consultant with an exercise price of $4.81. The options will vest in one year from the date of grant. Termination of a Material Definitive Agreement On March 17, 2022, the Company and Sorrento Therapeutics, Inc., have mutually agreed to terminate the August 11, 2021 term sheet, due to a disagreement between the parties concerning the timing, and terms and conditions, for the entry into the license agreement. Dyadic has not incurred any early termination penalties.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -URI http://asc.fasb.org/topic&trid=2122774 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662 + Details
Name: | us-gaap_SubsequentEventsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration